Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2014-03-12
AEs
1
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild COUGH — outcome: NOT RECOVERED/NOT RESOLVED; onset 2003; relationship: NONE
Data queries
No data queries.